323 related articles for article (PubMed ID: 29525824)
1. Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study.
Santi R; Cai T; Nobili S; Galli IC; Amorosi A; Comperat E; Nesi G
Virchows Arch; 2018 Apr; 472(4):605-613. PubMed ID: 29525824
[TBL] [Abstract][Full Text] [Related]
2. Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.
Gou Y; Ding W; Xu K; Wang H; Chen Z; Tan J; Xia G; Ding Q
Int Urol Nephrol; 2015 Feb; 47(2):289-93. PubMed ID: 25388353
[TBL] [Abstract][Full Text] [Related]
3. Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers.
Bruyere F; Namdarian B; Corcoran NM; Pedersen J; Ockrim J; Voelzke BB; Mete U; Costello AJ; Hovens CM
Urol Oncol; 2010; 28(6):591-6. PubMed ID: 19162513
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
5. SLUG expression is an indicator of tumour recurrence in high-grade endometrial carcinomas.
Kihara A; Wakana K; Kubota T; Kitagawa M
Histopathology; 2016 Sep; 69(3):374-82. PubMed ID: 27003026
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up.
Mathis C; Lascombe I; Monnien F; Bittard H; Kleinclauss F; Bedgedjian I; Fauconnet S; Valmary-Degano S
BMC Cancer; 2018 Dec; 18(1):1239. PubMed ID: 30526555
[TBL] [Abstract][Full Text] [Related]
7. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
8. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.
Singh R; Ansari JA; Maurya N; Mandhani A; Agrawal V; Garg M
Clin Genitourin Cancer; 2017 Apr; 15(2):e187-e197. PubMed ID: 27601277
[TBL] [Abstract][Full Text] [Related]
10. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
11. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer.
Kim JH; Park J
Hum Pathol; 2014 Sep; 45(9):1830-8. PubMed ID: 24957789
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
14. Expression of transcription factors snail, slug, and twist in human bladder carcinoma.
Yu Q; Zhang K; Wang X; Liu X; Zhang Z
J Exp Clin Cancer Res; 2010 Sep; 29(1):119. PubMed ID: 20809941
[TBL] [Abstract][Full Text] [Related]
15. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
[TBL] [Abstract][Full Text] [Related]
16. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.
Han B; Cui D; Jing Y; Hong Y; Xia S
World J Urol; 2014 Feb; 32(1):149-55. PubMed ID: 24616912
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases.
Pan CC; Chang YH; Chen KK; Yu HJ; Sun CH; Ho DM
Am J Clin Pathol; 2010 May; 133(5):788-95. PubMed ID: 20395527
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladder.
Hori S; Miyake M; Onishi S; Tatsumi Y; Morizawa Y; Nakai Y; Anai S; Tanaka N; Fujimoto K
Oncol Rep; 2016 Oct; 36(4):2117-25. PubMed ID: 27573985
[TBL] [Abstract][Full Text] [Related]
20. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection.
Muramaki M; Miyake H; Terakawa T; Kumano M; Sakai I; Fujisawa M
Urol Oncol; 2012; 30(2):161-6. PubMed ID: 20451421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]